Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2001, Telegraph Hill Partners is a venture capital firm based in San Francisco, California. The firm specializes in providing growth capital to life science, medical device, and healthcare companies. They manage a portfolio of six companies and focus on helping these businesses achieve their growth objectives.
Telegraph Hill Partners invests in private life science and healthcare companies that possess novel technologies and a solid customer base. Their investment strategy targets growth areas within healthcare, including discovery tools, diagnostics, healthcare IT, and medical devices. The firm provides capital and strategic guidance to support growth equity and acquisitions.
Notable portfolio companies include: AccuMetrics, acquired by ITC Nexus in 2013; Agena Bioscience, acquired by Mesa Laboratories in 2021; Akoya Biosciences, which went public in 2021 and was acquired by Quanterix in 2025; Asuragen, acquired by Bio-Techne in 2021; LDR, which went public in 2013 and was acquired by Zimmer Biomet in 2016; and Nimble Therapeutics, acquired by AbbVie in 2025.
Email info@thpartners.net with your deck to pitch to Telegraph Hill Partners.
Yes, Telegraph Hill Partners often leads investment rounds in their portfolio companies, providing both capital and strategic support.
The firm is open to follow-on investments, particularly in companies that demonstrate strong growth potential and align with their investment thesis.
Specific fund size details are not disclosed, but the firm focuses on growth equity investments in the life sciences and healthcare sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.